Screening and surveillance of oesophageal varices in patients with HCV-positive liver cirrhosis successfully treated by direct-acting antiviral agents

Autor: Alessia Ciancio, Davide Giuseppe Ribaldone, Rossella Salamone, Mauro Bruno, Stefania Caronna, Wilma Debernardi Venon, Chiara Giordanino, Alessandra Mondardini, Alessandro Musso, Marco Pennazio, Emanuela Rolle, Marco Sacco, Tatiana Sprujevnik, Claudio De Angelis, Giorgio Maria Saracco

Publikováno v: Liver international : official journal of the International Association for the Study of the Liver. 42(5)

limited evidence is available to guide hepatologists regarding endoscopic surveillance of oesophageal varices (EV) in Hepatitis C Virus (HCV)-positive cirrhotic patients achieving a sustained virologic response. To address these issues, we conducted

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9cb551d842b271abd3f56c6af02cfa68
https://pubmed.ncbi.nlm.nih.gov/35220668

Rifabutin-Based Rescue Therapy for Helicobacter pylori Eradication: A Long-Term Prospective Study in a Large Cohort of Difficult-to-Treat Patients

Autor: Chiara Giordanino, M. Baronio, A. Morgando, Giorgio Maria Saracco, Davide Giuseppe Ribaldone, Claudio De Angelis, Rinaldo Pellicano, Tatiana Sprujevnik, Marco Astegiano, Sharmila Fagoonee, Marilena Durazzo

Publikováno v: Journal of Clinical Medicine, Vol 8, Iss 2, p 199 (2019)
Journal of clinical medicine 8 (2019): 199. doi:10.3390/jcm8020199
info:cnr-pdr/source/autori:Ribaldone, Davide Giuseppe; Fagoonee, Sharmila; Astegiano, Marco; Durazzo, Marilena; Morgando, Anna; Sprujevnik, Tatiana; Giordanino, Chiara; Baronio, Monica; De Angelis, Claudio; Saracco, Giorgio Maria; Pellicano, Rinaldo/titolo:Rifabutin-Based Rescue Therapy for Helicobacter pylori Eradication: A Long-Term Prospective Study in a Large Cohort of Difficult-to-Treat Patients/doi:10.3390%2Fjcm8020199/rivista:Journal of clinical medicine/anno:2019/pagina_da:199/pagina_a:/intervallo_pagine:199/volume:8
Journal of Clinical Medicine
Volume 8
Issue 2

The most commonly used regimens fail to eradicate Helicobacter pylori (H. pylori) infection in 5&ndash
10% of patients. Those not cured with treatments based on amoxicillin, clarithromycin, nitroimidazoles, fluoroquinolones, bismuth or tetracycl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e26ffe77d8e0701e7eb5957920e9f7e
https://www.mdpi.com/2077-0383/8/2/199

Rifabutin-Based Rescue Therapy for

Autor: Davide Giuseppe, Ribaldone, Sharmila, Fagoonee, Marco, Astegiano, Marilena, Durazzo, Anna, Morgando, Tatiana, Sprujevnik, Chiara, Giordanino, Monica, Baronio, Claudio, De Angelis, Giorgio Maria, Saracco, Rinaldo, Pellicano

Publikováno v: Journal of Clinical Medicine

The most commonly used regimens fail to eradicate Helicobacter pylori (H. pylori) infection in 5–10% of patients. Those not cured with treatments based on amoxicillin, clarithromycin, nitroimidazoles, fluoroquinolones, bismuth or tetracycline have

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::c6b6c3c9dba472c51ddb15826424cab3
https://pubmed.ncbi.nlm.nih.gov/30736338

Durability of the response to peginterferon-α2b and ribavirin in patients with chronic hepatitis C

Autor: Simona Marenco, C. Colletta, Marco Sacco, Simone Ceretto, Giovannino Ciccone, Alessia Ciancio, Chiara Giordanino, Antonio Traverso, Antonio Picciotto, Dario Mazzucco, Antonina Smedile, Carlo Smirne, Giorgio Maria Saracco, Mario Rizzetto, Tiziano De Blasi, Alessandro Grasso, Mario Pirisi, Giuseppe Cariti, D Simondi

Publikováno v: European Journal of Gastroenterology & Hepatology. 26:52-58

OBJECTIVES To evaluate whether, in chronic hepatitis C-positive naive patients recruited in the routine clinical setting and treated with pegylated-interferon-α2b (Peg-IFN) and ribavirin (RBV), the sustained virologic response (SVR) is durable over

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::502406a5daf64c807b8d586f409d30a8
https://doi.org/10.1097/meg.0b013e328362dc99

Safety of propofol in cirrhotic patients undergoing colonoscopy and endoscopic retrograde cholangiography

Autor: Giorgio Maria Saracco, Emanuela Fagà, D. Reggio, Giovannino Ciccone, Mauro Bruno, Patrizia Carucci, Mario Rizzetto, Mariella De Cento, Chiara Giordanino, C. Barletti, Alessandro Musso, Rinaldo Pellicano, Wilma Debernardi Venon, Claudio De Angelis, Sharmila Fagoonee, Simone Ceretto

Publikováno v: European journal of gastroenterology & hepatology 24 (2012): 70–76. doi:10.1097/MEG.0b013e32834c16ab
info:cnr-pdr/source/autori:Faga, Emanuela; De Cento, Mariella; Giordanino, Chiara; Barletti, Claudio; Bruno, Mauro; Carucci, Patrizia; De Angelis, Claudio; Venon, Wilma Debernardi; Musso, Alessandro; Reggio, Dario; Fagoonee, Sharmila; Pellicano, Rinaldo; Ceretto, Simone; Ciccone, Giovannino; Rizzetto, Mario; Saracco, Giorgio/titolo:Safety of propofol in cirrhotic patients undergoing colonoscopy and endoscopic retrograde cholangiography: results of a prospective controlled study/doi:10.1097%2FMEG.0b013e32834c16ab/rivista:European journal of gastroenterology & hepatology/anno:2012/pagina_da:70/pagina_a:76/intervallo_pagine:70–76/volume:24

Background and aims: Safety of propofol sedation in patients with liver cirrhosis undergoing colonoscopy or endoscopic retrograde cholangiopancreatography (ERCP) remains to be studied. The aim of this study was to investigate whether the use of propo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa266ca547c9b7ca025c3a1c50780f30
https://doi.org/10.1097/meg.0b013e32834c16ab